Activity of PD-1 blockade with Nivolumab among patients with recurrent atypical/anaplastic meningioma: Phase II trial results.
Wenya Linda BiLakshmi NayakDavid M MeredithJoseph DriverZiming DuSamantha HoffmanYvonne LiEudocia Quant LeeRameen BeroukhimMikael RinneRicardo McFaline-FigueroaUgonma ChukwuekeChristine McCluskeySarah GaffeyAndrew D CherniackJennifer StefanikLisa DohertyChristina TaubertMeghan CifrinoDeborah LaFrankieThomas GraillonPatrick Y WenKeith L LigonOssama Al-MeftyRaymond Y HuangAlona MuzikanskyE Antonio ChioccaSandro SantagataIan F DunnDavid A ReardonPublished in: Neuro-oncology (2021)
Nivolumab was well tolerated but failed to improve PFS-6, although a subset of patients appeared to derive benefit. Low levels of TMB and TIL density were typically observed. NANO assessment of neurologic function contributed to outcome assessment. Future studies may consider rationally designed combinatorial regimens.